InvestSMART

Microba Life Sciences Limited (ASX: MAP) - Announcements

Current share price for MAP : $0.056 0.002 (3.70%)+

ASX company news and announcements for Microba Life Sciences Limited (MAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Microba Life Sciences Limited (MAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Microba Life Sciences Limited (MAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Microba Life Sciences Limited (MAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$40 Excluded Information Notice 19 Oct 2023 9:16AM $0.320 $0.056 fallen by 82.50%
$40 Proposed issue of securities - MAP 19 Oct 2023 9:08AM $0.320 $0.056 fallen by 82.50%
$40 Application for quotation of securities - MAP 19 Oct 2023 9:02AM $0.320 $0.056 fallen by 82.50%
$40 Invivo Clinical Acquisition and Capital Raising Presentation 19 Oct 2023 8:55AM $0.320 $0.056 fallen by 82.50%
$40 Microba to acquire UK microbiome leader Invivo Clinical 19 Oct 2023 8:54AM $0.320 $0.056 fallen by 82.50%
$40 Q1 FY24 Quarterly Activities Report & Appendix 4C 19 Oct 2023 8:52AM $0.320 $0.056 fallen by 82.50%
$40 Trading Halt 19 Oct 2023 8:43AM $0.320 $0.056 fallen by 82.50%
$40 Date of AGM and Closing Date for Director Nominations 12 Oct 2023 9:04AM $0.310 $0.056 fallen by 81.94%
$40 Appendix 4G 30 Aug 2023 9:16AM $0.350 $0.056 fallen by 84%
$40 Appendix 4E & Annual Report 30 Aug 2023 9:15AM $0.350 $0.056 fallen by 84%
$40 Corporate Governance Statement 30 Aug 2023 8:58AM $0.350 $0.056 fallen by 84%
$40 Microba Completes Dosing in Phase I IBD Clinical Trial 25 Aug 2023 8:55AM $0.350 $0.056 fallen by 84%
$40 Notification regarding unquoted securities - MAP 4 Aug 2023 5:21PM $0.385 $0.056 fallen by 85.45%
$40 Q4 FY23 Quarterly Investor Presentation 27 Jul 2023 9:11AM $0.315 $0.056 fallen by 82.22%
$40 Q4 FY23 Quarterly Activities Report & Appendix 4C 27 Jul 2023 9:04AM $0.315 $0.056 fallen by 82.22%
$40 Details of Q4 FY23 Quarterly Report, Appendix 4C & Webinar 25 Jul 2023 9:02AM $0.300 $0.056 fallen by 81.33%
$40 Microba to Present at 17th Bioshares Biotech Summit 24 Jul 2023 9:09AM $0.315 $0.056 fallen by 82.22%
$40 Ceasing to be a substantial holder 7 Jul 2023 4:08PM $0.310 $0.056 fallen by 81.94%
$40 First Distribution Agreement Executed with Sonic Healthcare 5 Jul 2023 9:07AM $0.300 $0.056 fallen by 81.33%
$40 Notification of cessation of securities - MAP 30 Jun 2023 5:06PM $0.300 $0.056 fallen by 81.33%
$40 Microba Commences Phase I Clinical Trial for IBD Therapeutic 28 Jun 2023 9:04AM $0.295 $0.056 fallen by 81.02%
$40 MRFF Grant Awarded to QUT, In Collaboration With Microba 27 Jun 2023 11:17AM $0.290 $0.056 fallen by 80.69%
$40 Notification of cessation of securities - MAP 16 Jun 2023 4:29PM $0.295 $0.056 fallen by 81.02%
$40 Microba receives two AusIndustry Advanced Overseas Findings 14 Jun 2023 2:06PM $0.275 $0.056 fallen by 79.64%
$40 Appendix 3Z - Final Director's Interest Notice 14 Jun 2023 9:03AM $0.275 $0.056 fallen by 79.64%

201 - 225 of 697 results

Page 9 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.